Physician profile
Joseph S Peyton
NPI 1538145925
$6,970.35
in general payments reported to CMS, 2019-2025
52 companies · $1,289 in 2025
The $1,289 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $685 · 2021: $1,157 · 2022: $1,206 · 2023: $1,282 · 2024: $385 · 2025: $1,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,703 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,702.60 |
| Education | $253.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $645.70 | 2021-2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Vanda Pharmaceuticals INC. | $508.55 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $406.85 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $396.47 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $391.61 | 2019-2022 | |
| Ucb, INC. | $362.25 | 2019-2023 | Briviact, Nayzilam |
| Astrazeneca Pharmaceuticals LP | $285.00 | 2019-2025 | Farxiga, Lokelma |
| Sk Life Science, INC. | $283.88 | 2020-2025 | |
| Pfizer INC. | $282.43 | 2019-2025 | |
| Lundbeck LLC | $258.09 | 2022-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $228.10 | 2023 | Gemtesa, Aptiom |
| Amgen INC. | $212.52 | 2020-2025 | Evenity |
| Actelion Pharmaceuticals US, INC. | $193.57 | 2023-2024 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $172.38 | 2020-2023 | Verquvo, Lagevrio |
| Otsuka America Pharmaceutical, INC. | $164.30 | 2022-2025 | Rexulti, Nuedexta |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Peyton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.